Tryptamine Therapeutics Appoints New Auditor; Shares Fall 7%

MT NewswiresJan 5 23:10 ET

Year Wrapped: Tryptamine Therapeutics 2024 Milestones, Clinical Breakthroughs & 2025 Vision | ASX:TYP, OTC:TYPTF

Proactive InvestorsDec 19, 2024 18:25 ET

Tryptamine Therapeutics Fields Positive Early Results in Phase 2a Irritable Bowel Syndrome Trial

Investing.com Dec 17, 2024 18:56 ET

Tryptamine Therapeutics Phase 1b Study Refines Dose of IV Psilocin in Obese Subjects

Investing.com Dec 15, 2024 19:45 ET

Tryptamine Therapeutics Issues 47 Million Unquoted Options

TipRanksDec 2, 2024 00:47 ET

Tryptamine Therapeutics Completes Dosing of First Subject in Obesity Study

MT NewswiresNov 21, 2024 21:39 ET